Web Sify
Follow us on
Mail
Print

Export pushes Cipla net 62%

Source : BUSINESS_STANDARD
Last Updated: Mon, Nov 05, 2012 19:10 hrs
Hamied, chairman and MD of Indian generic drugmaker Cipla, poses for picture in front of cabinet containing company's products before interview in Mumbai

Cipla, India's second largest pharma company by value, has posted a 62 per cent growth in net profit for the quarter ended September 30. The company's profit after tax grew to Rs 500 crore, up from Rs 309 crore a year before, on the back of increased growth in formulation exports. Exports of formulations grew 38 per cent to Rs 1,039 crore, up from Rs 752 crore. On Monday, shares of Cipla closed at Rs 380.45, up 0.9 per cent on the BSE.

The Rs 7,000-crore Cipla's gross revenues for the second quarter grew 24 per cent to Rs 2,220 crore, up from Rs 1,796 crore in Q2 FY 11-12. Material cost, at 36 per cent of total sales, also decreased by 4.2 per cent during Q2, said the company statement.

Domestic revenues grew by 14 per cent to Rs 962 crore during Q2 FY 12-13, up from Rs 847 crore. The growth in domestic revenues was largely on account of growth in the anti-asthma, antibiotics and cardiovascular therapy segments, added the company statement.

Exports of active pharmaceuticals ingredients (APIs) grew nine per cent to Rs 174 crore during Q2 FY 12-13, from Rs 159 crore. The growth in export revenues was primarily due to growth in anti-depressant, anti-ulcerant and anti-asthma segments, according to the statement.


More from Sify:
blog comments powered by Disqus
most popular on facebook
talking point on sify finance